Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 17.77% is 862% above its 5-year average of -2.33%, near the high end of its 5-year range (-27.64%–17.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.04% above its 12-month average of 16.75%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 17.77%.
RETURN ON EQUITY (ROE)
17.77%
RETURN ON EQUITY (ROE) AVG TTM
16.75%
RETURN ON EQUITY (ROE) AVG 3Y
10.74%
RETURN ON EQUITY (ROE) AVG 5Y
-2.33%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.04%
CURRENT VS 3Y AVG
+65.36%
CURRENT VS 5Y AVG
+861.64%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.15%
median of 634 covered companies
CURRENT VS SECTOR MEDIAN
+144.26%
vs the sector median at left
Krystal Biotech, Inc.
Market Cap
$9.75B
Return on Equity (ROE)
17.77%
TTM Avg
16.75%
3Y Avg
10.74%
5Y Avg
-2.33%
Market Cap
$9.71B
Return on Equity (ROE)
12.77%
TTM Avg
11.88%
3Y Avg
12.69%
5Y Avg
13.50%
Market Cap
$9.98B
Return on Equity (ROE)
3.10%
TTM Avg
-8.94%
3Y Avg
-15.72%
5Y Avg
1.14%
Market Cap
$10.01B
Return on Equity (ROE)
-0.17%
TTM Avg
18.91%
3Y Avg
22.60%
5Y Avg
24.60%
Market Cap
$9.46B
Return on Equity (ROE)
-38.59%
TTM Avg
-21.29%
3Y Avg
-24.61%
5Y Avg
-26.58%
Market Cap
$10.09B
Return on Equity (ROE)
1.97%
TTM Avg
0.51%
3Y Avg
3.14%
5Y Avg
3.97%
Market Cap
$9.39B
Return on Equity (ROE)
26.39%
TTM Avg
25.41%
3Y Avg
19.99%
5Y Avg
14.02%
Market Cap
$10.12B
Return on Equity (ROE)
15.51%
TTM Avg
15.81%
3Y Avg
15.92%
5Y Avg
17.27%
Market Cap
$9.32B
Return on Equity (ROE)
-2.97%
TTM Avg
3.00%
3Y Avg
15.91%
5Y Avg
17.66%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | $9.75B | 17.77% | 16.75% | 10.74% | -2.33% |
| Henry Schein, Inc. (HSIC)vs › | $9.71B | 12.77% | 11.88% | 12.69% | 13.50% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.98B | 3.10% | -8.94% | -15.72% | 1.14% |
| Molina Healthcare, Inc. (MOH)vs › | $10.01B | -0.17% | 18.91% | 22.60% | 24.60% |
| Vaxcyte, Inc. (PCVX)vs › | $9.46B | -38.59% | -21.29% | -24.61% | -26.58% |
| Repligen Corporation (RGEN)vs › | $10.09B | 1.97% | 0.51% | 3.14% | 3.97% |
| Insulet Corp. (PODD)vs › | $9.39B | 26.39% | 25.41% | 19.99% | 14.02% |
| The Ensign Group, Inc. (ENSG)vs › | $10.12B | 15.51% | 15.81% | 15.92% | 17.27% |
| Bruker Corporation (BRKR)vs › | $9.32B | -2.97% | 3.00% | 15.91% | 17.66% |
| Align Technology, Inc. (ALGN)vs › | $10.23B | 9.77% | 10.54% | 10.84% | 19.93% |
ROE
17.8%
ROA
16.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 17.77% |
| 2026-03-31 | 17.63% |
| 2025-12-31 | 16.80% |
| 2025-09-30 | 17.48% |
| 2025-06-30 | 14.10% |
| 2025-03-31 | 12.59% |
| 2024-12-31 | 9.42% |
| 2024-09-30 | 5.91% |
| 2024-06-30 | 12.63% |
| 2024-03-31 | 7.15% |
| 2023-12-31 | 1.40% |
| 2023-09-30 | -3.94% |
| 2023-06-30 | -21.50% |
| 2023-03-31 | -27.64% |
| 2022-12-31 | -26.80% |
| 2022-09-30 | -23.99% |
| 2022-06-30 | -20.65% |
| 2022-03-31 | -18.91% |
| 2021-12-31 | -11.72% |
| 2021-09-30 | -14.24% |
| 2021-06-30 | -12.46% |
| 2021-03-31 | -9.90% |
| 2020-12-31 | -11.01% |
| 2020-09-30 | -9.00% |
| 2020-06-30 | -7.04% |
| 2020-03-31 | -10.24% |
| 2019-12-31 | -9.41% |
| 2019-09-30 | -8.40% |
| 2019-06-30 | -8.03% |
| 2019-03-31 | -11.74% |
| 2018-12-31 | -9.62% |
| 2018-09-30 | -16.40% |
| 2018-06-30 | -24.50% |
| 2018-03-31 | -20.20% |
| 2017-12-31 | -16.01% |
| 2017-09-30 | -14.25% |
| 2017-06-30 | -64.90% |
